Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases

Journal of Surgical Oncology

Volumn 115, Issue 4, 2017, Pages 480-487

  Connell, Louise C ^a   Boucher, Taryn M ^a   Chou, Joanne F ^a   Capanu, Marinela ^a   Maldonado, Stephanie ^a   Kemeny, Nancy E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CEA; colorectal cancer; KRAS status; LDH; liver metastases

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; LACTATE DEHYDROGENASE; OXALIPLATIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ABDOMINAL CANCER; ABDOMINAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; INOPERABLE CANCER; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; METASTASIS; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; BLOOD; COLORECTAL NEOPLASMS; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES;

EID: 85007124127     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24536     Document Type: Article

References (22)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics. CA Cancer J Clin. 2012; 65:87–108.
2. Pozzo C, Barone C, Kemeny N. Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treat Rev. 2008; 34:293–301.
3. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012; 104:228–239.
4. Baskin Y, Dagdeviren YK, Calibasi G, et al. KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas. J Gastrointest Oncol. 2014; 5:265–269.
5. Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010; 17:572–578.
6. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008; 26:374–379.
7. Díaz-Rubio E, Gómez-España A, Massutí B, et al. Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. PLoS ONE. 2012; 7:e47345.
8. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011; 17:4892–4900.
9. Kemeny N, Braun DW. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med. 1983; 74:786–794.
10. Scartozzi M, Giampieri R, Maccaroni E, et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer. 2012; 106:799–804.
11. Giessen C, Fischer von Weikersthal L, Laubender RP, et al. Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial. Br J Cancer. 2013; 109:1428–1436.
12. Duffy MJ, van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003; 39:718–727.
13. Aggarwal C, Meropol NJ, Punt CJ, et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol. 2013; 24:420–428.
14. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230:309–318.
15. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16:1141–1154.
16. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008; 26:3913–3915.
17. Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer. 1986; 57:1866–1870.
18. Graf W, Glimelius B, Påhlman L, Bergström R. Determinants of prognosis in advanced colorectal cancer. Eur J Cancer. 1991; 27:1119–1123.
19. Graf W, Bergstrom R, Pahlman L, Glimelius B. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur J Cancer 1994; 30A:453–457.
20. Webb A, Scott-Mackie P, Cunningham D, et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol. 1995; 6:581–587.
21. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001; 85:692–696.
22. Köhne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13:308–317.